Company Earnings Update 4 minutesRegister for Free AccessCVS Health (NYSE: CVS) 2Q19 Results: Narrows Profit and Earnings Outlook on Aetna Strength Coresight Research August 9, 2019 Executive Summary CVS Health reported 2Q19 revenues of $63.4 billion, up 35.2% year over year and ahead of the consensus estimate. Diluted EPS was $1.49, versus a loss per share of $2.52 in 2Q18. CVS closed its acquisition of Aetna in November 2018 and was the primary growth driver during the quarter, along with increased volumes and brand name drug price inflation. For FY19, CVS narrowed its adjusted EPS guidance range to $6.89-7.00 from $6.75-6.90. Already a subscriber? Log in You are currently viewing a preview of this report. Please select an access option to view the full report. Hide Options - Show Options + Get unlimited access to all our research with one of our subscription plans. View Subscription Plans or Contact us to purchase this report. Contact us ✕ This document was generated for Other research you may be interested in: Generative AI Latest: Indian Conglomerates Enter the Space, the US Drives the Responsible Use of AI, Adobe Launches New ProductsDrugstore and Pharmacy Shopping in Focus—CVS and Walgreens Are the Top Choices: US Consumer Survey InsightsWeinswig’s Weekly: Roblox and Fortnite Set the Stage for the Developing MetaverseChinese New Year 2024 Review: Revealing Trends Amid Evolving Preferences—China Retail Insights
